United States - English - NLM (National Library of Medicine)

yiling pharmaceutical, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - 1.2 chronic idiopathic urticaria levocetirizine dihydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride tablet is contraindicated in: 4.1 patients with known hypersensitivity patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)]. 4.2 patients with end-stage renal disease patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis 4.3 pediatric patients with impaired renal function children 6 months to 11 years of age with impaired renal function 8.1 pregnancy risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women are insufficient to identify any drug-ass

United States - English - NLM (National Library of Medicine)

avkare, inc. - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - levocetirizine dihydrochloride 5 mg - 1.2 perennial allergic rhinitis levocetirizine dihydrochloride tablets are indicated for the relief of symptoms associated with perennial allergic rhinitis in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride tablet is contraindicated in: 4.1 patients with known hypersensitivity patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)]. 4.2 patients with end-stage renal disease patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis 4.3 pediatric patients with impaired renal function children 6 months to 11 years of age with impaired renal function 8.1 pregnancy pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictiv

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 2.194 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 5.485 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 1.097 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - remifentanil hydrochloride, quantity: 1.097 mg - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures, including cardiac surgery, in adults;,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical, but not cardiac procedures, in children aged 1?12 years;,- for continuation as an analgesic into the immediate post-operative period under the close supervision of medically-qualified persons trained in the use of anaesthetic agents, during transition to longer-acting analgesia following adult cardiac surgery ? when endotracheal intubation and controlled ventilation are anticipated;,- for provision of analgesia and sedation in mechanically-ventilated intensive care patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - remifentanil hydrochloride, quantity: 2.194 mg - injection, powder for - excipient ingredients: glycine; hydrochloric acid - remifentanil is indicated:,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures, including cardiac surgery, in adults;,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical, but not cardiac procedures, in children aged 1?12 years;,- for continuation as an analgesic into the immediate post-operative period under the close supervision of medically-qualified persons trained in the use of anaesthetic agents, during transition to longer-acting analgesia following adult cardiac surgery ? when endotracheal intubation and controlled ventilation are anticipated;,- for provision of analgesia and sedation in mechanically-ventilated intensive care patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - remifentanil hydrochloride, quantity: 5.485 mg - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures, including cardiac surgery, in adults;,- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical, but not cardiac procedures, in children aged 1?12 years;,- for continuation as an analgesic into the immediate post-operative period under the close supervision of medically-qualified persons trained in the use of anaesthetic agents, during transition to longer-acting analgesia following adult cardiac surgery ? when endotracheal intubation and controlled ventilation are anticipated;,- for provision of analgesia and sedation in mechanically-ventilated intensive care patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; polysorbate 80; povidone; microcrystalline cellulose; magnesium stearate; glycine; titanium dioxide; hypromellose; carnauba wax; macrogol 400 - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.,raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis.raloxifene is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer.

United States - English - NLM (National Library of Medicine)

cardinal health - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride and epinephrine injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.